Clinical characteristics of patients in this study
| Patient . | Stage . | CD4 count cells/mm3 . | Viral load copies/ mL . | A2.1/B8 . | Rx . |
|---|---|---|---|---|---|
| 136 | B2 | 410 | 4 338 | A2 | AZT |
| 146 | A2 | 280 | ND | A2, B8 | None |
| 203 | A2 | 490 | < 500 | A2, B8 | AZT, ddI |
| 204 | B3 | 185 | 8 300 | A2, B8 | ddC |
| 215 | B3 | 150 | 46 322 | A2 | AZT, ddC |
| 219 | A2 | 370 | 1 512 | A2 | AZT |
| 224 | A3 | 180 | ND | B8 | AZT, ddC |
| 225 | B3 | 124 | ND | B8 | ddI |
| 226 | C3 | 130 | 65 438 | B8 | None |
| 230 | A2 | 250 | 132 500 | B8 | AZT, 3TC |
| 237 | C2 | 260 | 3 430 | A2 | AZT, 3TC |
| 307 | B2 | 283 | 8 633 | A2 | None |
| 350 | A1 | 1005 | 70 | A2 | AZT, ddC, 3TC |
| 501 | B2 | 307 | < 50 | A2 | HAART |
| 606 | A2 | 615 | < 50 | A2 | HAART |
| 701 | B3 | 71 | < 50 | A2 | HAART |
| 703 | A1 | 529 | < 50 | A2 | ddI, d4T |
| 705 | A2 | 650 | 13 000 | A2 | ddI, d4T, efavirenz |
| CW1 | C3 | 348 | 68 618 | B8 | None |
| CW3 | B1 | 518 | 175 135 | B8 | None |
| CW4 | B3 | 38 | 52 363 | A2, B8 | 3TC, d4T, RTV, SQV |
| CW5 | A1 | 590 | 23 565 | A2 | None, LTNP |
| CW6 | C3 | 739 | < 50 | A2 | 3TC, d4T, ABV, efavirenz |
| CW7 | A2 | 437 | < 50 | A2 | None, LTNP |
| CW9 | B3 | 477 | < 100 | A2 | AZT, 3TC, RTV |
| CW10 | C3 | 280 | < 100 | B8 | AZT, 3TC, RTV |
| CW11 | B2 | 574 | < 50 | B8 | 3TC, d4T, NFV |
| CW14 | A1 | 670 | 54 000 | B8 | None, LTNP |
| CW16 | A1 | 694 | 549 | A2 | None, LTNP |
| CW18 | A1 | 599 | < 50 | A2 | None, LTNP |
| CW19 | A2 | 286 | 746 | A2 | AZT, 3TC, ± efavirenz, ± NFV |
| CW20 | A2 | 467 | 8 400 | B8 | None, LTNP |
| CW24 | B1 | 718 | 103 | A2 | AZT, 3TC, RTV, SQV |
| CW28 | C3 | 539 | < 50 | A2 | 3TC, d4T, Kaletra |
| CW29 | B3 | 817 | < 50 | B8 | AZT, ddI, IDV |
| Patient . | Stage . | CD4 count cells/mm3 . | Viral load copies/ mL . | A2.1/B8 . | Rx . |
|---|---|---|---|---|---|
| 136 | B2 | 410 | 4 338 | A2 | AZT |
| 146 | A2 | 280 | ND | A2, B8 | None |
| 203 | A2 | 490 | < 500 | A2, B8 | AZT, ddI |
| 204 | B3 | 185 | 8 300 | A2, B8 | ddC |
| 215 | B3 | 150 | 46 322 | A2 | AZT, ddC |
| 219 | A2 | 370 | 1 512 | A2 | AZT |
| 224 | A3 | 180 | ND | B8 | AZT, ddC |
| 225 | B3 | 124 | ND | B8 | ddI |
| 226 | C3 | 130 | 65 438 | B8 | None |
| 230 | A2 | 250 | 132 500 | B8 | AZT, 3TC |
| 237 | C2 | 260 | 3 430 | A2 | AZT, 3TC |
| 307 | B2 | 283 | 8 633 | A2 | None |
| 350 | A1 | 1005 | 70 | A2 | AZT, ddC, 3TC |
| 501 | B2 | 307 | < 50 | A2 | HAART |
| 606 | A2 | 615 | < 50 | A2 | HAART |
| 701 | B3 | 71 | < 50 | A2 | HAART |
| 703 | A1 | 529 | < 50 | A2 | ddI, d4T |
| 705 | A2 | 650 | 13 000 | A2 | ddI, d4T, efavirenz |
| CW1 | C3 | 348 | 68 618 | B8 | None |
| CW3 | B1 | 518 | 175 135 | B8 | None |
| CW4 | B3 | 38 | 52 363 | A2, B8 | 3TC, d4T, RTV, SQV |
| CW5 | A1 | 590 | 23 565 | A2 | None, LTNP |
| CW6 | C3 | 739 | < 50 | A2 | 3TC, d4T, ABV, efavirenz |
| CW7 | A2 | 437 | < 50 | A2 | None, LTNP |
| CW9 | B3 | 477 | < 100 | A2 | AZT, 3TC, RTV |
| CW10 | C3 | 280 | < 100 | B8 | AZT, 3TC, RTV |
| CW11 | B2 | 574 | < 50 | B8 | 3TC, d4T, NFV |
| CW14 | A1 | 670 | 54 000 | B8 | None, LTNP |
| CW16 | A1 | 694 | 549 | A2 | None, LTNP |
| CW18 | A1 | 599 | < 50 | A2 | None, LTNP |
| CW19 | A2 | 286 | 746 | A2 | AZT, 3TC, ± efavirenz, ± NFV |
| CW20 | A2 | 467 | 8 400 | B8 | None, LTNP |
| CW24 | B1 | 718 | 103 | A2 | AZT, 3TC, RTV, SQV |
| CW28 | C3 | 539 | < 50 | A2 | 3TC, d4T, Kaletra |
| CW29 | B3 | 817 | < 50 | B8 | AZT, ddI, IDV |
Disease staging was determined by the lowest CD4 count and in accordance with the CDC classification system. ND indicates not done; AZT, zidovidine; ddI, dideoxyinosine; ddC, dideoxycytosine; 3TC, lamivudine; d4T, stavudine; RTV, ritonavir; SQV, saquinavir; NFV, nelfinavir; IDV, indinavir; ABV, abacavir; Kaletra, lopinavir/ritonavir; LTNP, long-term nonprogressor.